Показано 0 из 0
Дата |
---|
09.05.2024 |
06.05.2024 |
22.04.2024 |
02.04.2024 |
26.03.2024 |
21.03.2024 |
20.03.2024 |
18.03.2024 |
12.03.2024 |
11.03.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.03
|
|
0.036
|
0.036
|
0.036
|
0.036
|
|
|
|
1.00
|
0.03
|
|
0.07
|
0.07
|
0.07
|
0.07
|
|
|
10.22
|
3.00
|
|
|
0.0691
|
0.0691
|
0.0691
|
0.0691
|
|
|
|
1.00
|
|
0.079
|
0.033
|
0.033
|
0.0699
|
0.0699
|
|
|
6.60
|
4.00
|
0.025
|
0.18
|
0.066449
|
0.066449
|
0.066449
|
0.066449
|
|
|
|
1.00
|
0.025
|
0.18
|
0.0698
|
0.0698
|
0.0698
|
0.0698
|
|
|
|
1.00
|
0.025
|
0.08
|
0.0698
|
0.0698
|
0.0698
|
0.0698
|
|
|
567.32
|
2.00
|
0.0111
|
0.18
|
0.0352
|
0.0352
|
0.0352
|
0.0352
|
|
|
|
1.00
|
0.0111
|
0.18
|
0.0334
|
0.0334
|
0.0334
|
0.0334
|
|
|
|
1.00
|
0.0111
|
0.18
|
0.0599
|
0.0599
|
0.0599
|
0.0599
|
|
|
|
1.00
|
Estrella Immunopharma, Inc. operates as a preclinical-stage biopharmaceutical company. The Company focuses on developing CD19 and CD22-targeted T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella Immunopharma serves customers worldwide.